[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 12 of about 12
2. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • Synovial sarcoma and liposarcoma subtypes have a better prognosis.
  • However, the overall poor outcome of these patients indicates the need to continue the search for more effective agents.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Goss G, Demetri G: Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol; 2000 Aug;9(2):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
  • For patients with recurrent and unresectable liposarcoma, treating the sarcoma while maintaining quality of life becomes the major therapeutic goal.
  • Such patients also represent ideal candidates for investigational approaches aimed at identifying new agents with which to treat this disease.
  • In addition to the development of new cytotoxic agents, patients may be candidates for novel strategies such as differentiation therapies or anti-angiogenic approaches.
  • [MeSH-major] Chromans / administration & dosage. Liposarcoma / drug therapy. Liposarcoma / surgery. Neoplasm Recurrence, Local / drug therapy. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / surgery. Thiazoles / administration & dosage. Thiazolidinediones

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094323.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Chromans; 0 / Thiazoles; 0 / Thiazolidinediones; I66ZZ0ZN0E / troglitazone
  • [Number-of-references] 26
  •  go-up   go-down


Advertisement
4. Andersson MK, Göransson M, Olofsson A, Andersson C, Aman P: Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop. BMC Cancer; 2010;10:249
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This could be a consequence of the ability of FUS-DDIT3 to hijack parts of normal adipose tissue development and reprogram primary cells to a liposarcoma-like phenotype.
  • [MeSH-major] Cell Nucleus / metabolism. Fibrosarcoma / metabolism. Liposarcoma, Myxoid / metabolism. Oncogene Proteins, Fusion / metabolism. Pregnancy Proteins / metabolism. RNA-Binding Protein FUS / metabolism. Signal Transduction. Transcription Factor CHOP / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Fluorescent Antibody Technique. Humans. Immunohistochemistry. Ligands. Mice. Mice, SCID. Neoplasm Transplantation. Protein Kinase Inhibitors / pharmacology. RNA Interference. Recombinant Fusion Proteins / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor B / metabolism


5. Morozov A, Downey RJ, Healey J, Moreira AL, Lou E, Franceschino A, Dogan Y, Leung R, Edgar M, LaQuaglia M, Maki RG, Moore MA: Benign mesenchymal stromal cells in human sarcomas. Clin Cancer Res; 2010 Dec 1;16(23):5630-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We show that a dedifferentiated liposarcoma cell line DDLS8817 posesses fat, bone, and cartilage trilineage differentiation potential characteristic of MSCs.
  • CONCLUSIONS: SDBMSCs/pericytes represent a previously undescribed stromal cell type in sarcoma that may contribute to tumor formation.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7223-36 [19010839.001]
  • [Cites] Cytotherapy. 2008;10(7):657-67 [18985472.001]
  • [Cites] Haematologica. 2009 Jan;94(1):127-30 [19029148.001]
  • [Cites] Trends Genet. 2009 Jan;25(1):30-8 [19054589.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1776-81 [19208848.001]
  • [Cites] Curr Opin Genet Dev. 2009 Feb;19(1):67-73 [19211240.001]
  • [Cites] Pathol Res Pract. 2009;205(5):339-45 [19157720.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1176:118-23 [19796239.001]
  • [Cites] Genes Dev. 2008 Mar 1;22(5):559-74 [18316475.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1388-93 [10728704.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5755-62 [11607825.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4200-11 [12082607.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1569-76 [12237927.001]
  • [Cites] Cancer Cell. 2002 Sep;2(3):175-8 [12242149.001]
  • [Cites] Cancer. 1977 Aug;40(2):744-55 [560905.001]
  • [Cites] Blood. 1980 Aug;56(2):289-301 [6994839.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):237-41 [8990192.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):569-75 [9816205.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6 [10097144.001]
  • [Cites] Science. 1999 Apr 2;284(5411):143-7 [10102814.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):513-20 [15950901.001]
  • [Cites] Cytotherapy. 2005;7(5):393-5 [16236628.001]
  • [Cites] Microvasc Res. 2006 May;71(3):163-74 [16624341.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7016-23 [16849546.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):161-9 [17200351.001]
  • [Cites] J Lipid Res. 2007 Jan;48(1):9-18 [17057226.001]
  • [Cites] Cancer Cell. 2007 May;11(5):421-9 [17482132.001]
  • [Cites] Lancet Oncol. 2007 Jun;8(6):513-24 [17540303.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8216-22 [17804735.001]
  • [Cites] Nature. 2007 Oct 4;449(7162):557-63 [17914389.001]
  • [Cites] Am J Pathol. 2008 Apr;172(4):1069-80 [18310505.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2176-85 [18381423.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14(7):1931-7 [18381930.001]
  • [Cites] Mol Cancer Res. 2008 Jun;6(6):929-36 [18567797.001]
  • [Cites] Mod Pathol. 2008 Aug;21(8):943-9 [18500263.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11851-6 [18697945.001]
  • [Cites] Cell Stem Cell. 2008 Sep 11;3(3):301-13 [18786417.001]
  • [Cites] Stem Cells. 2008 Sep;26(9):2287-99 [18566331.001]
  • [Cites] J Orthop Res. 2009 Jan;27(1):135-40 [18634019.001]
  • (PMID = 21138865.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024997; United States / NCRR NIH HHS / RR / RR024997-01; United States / NCRR NIH HHS / RR / KL2RR024997
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Il2rg protein, mouse; 0 / Interleukin Receptor Common gamma Subunit
  • [Other-IDs] NLM/ NIHMS224015; NLM/ PMC3820159
  •  go-up   go-down


6. Rossi S, Canal F, Licci S, Zanatta L, Laurino L, Gottardi M, Gherlinzoni F, Dei Tos AP: Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy. Hum Pathol; 2009 Jul;40(7):1040-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy.
  • Myxoid liposarcoma exhibits a peculiar clinical behavior, with a tendency to spread to serosal membranes, distant soft tissues, and bones, even in the absence of lung metastases.
  • We describe an exceptional case of metastatic myxoid liposarcoma of the spine associated with therapy-related refractory anemia with excess of blasts in a 37-year-old woman who underwent multi-agent chemotherapy for a myxoid liposarcoma of the left thigh.
  • Microscopic examination of the bone marrow biopsy revealed dysplastic features, with abnormal localization of immature precursors and micromegakaryocytes, and islands of undifferentiated oval small/medium-size cells, suggestive of acute myeloid leukemia arising in the setting of a myelodysplastic syndrome.
  • Cytogenetic analyses of bone marrow aspirate disclosed the presence of 2 different rearrangements, subsequently confirmed by fluorescent in situ hybridization and was crucial in making the correct diagnosis.
  • [MeSH-major] Liposarcoma, Myxoid / pathology. Myelodysplastic Syndromes / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Anemia, Refractory / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Cells / pathology. Chromosomes, Human, Pair 11. Combined Modality Therapy / adverse effects. Female. Humans. Leukemia, Myeloid, Acute / pathology. Soft Tissue Neoplasms / pathology. Thigh / pathology


7. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol; 2009 Sep 1;27(25):4188-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
  • PURPOSE: To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide.
  • PATIENTS AND METHODS: Patients were randomly assigned to one of two trabectedin regimens (via central venous access): 1.5 mg/m(2) 24-hour intravenous infusion once every 3 weeks (q3 weeks 24-hour) versus 0.58 mg/m(2) 3-hour IV infusion every week for 3 weeks of a 4-week cycle (qwk 3-hour).
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / administration & dosage. Drug Resistance, Neoplasm. Ifosfamide / therapeutic use. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Tetrahydroisoquinolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia. Disease-Free Survival. Drug Administration Schedule. Europe. Female. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. North America. Proportional Hazards Models. Risk Assessment. Time Factors. Treatment Failure. Young Adult


8. Mrad K, Sassi S, Smida M, Oubiche F, Mekni A, Romdhane KB: Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone. Pathologica; 2004 Dec;96(6):475-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with rhabdomyosarcomatous component or so-called malignant mesenchymoma of bone.
  • BACKGROUND: Primary malignant mesenchymoma of the bone is a rare neoplasm consisting of two or more unrelated malignant mesenchymal components.
  • The literature reports fewer than 20 cases, most of which were composed of osteosarcoma and liposarcoma.
  • OBSERVATION: We report an exceedingly rare case of primary malignant mesenchymoma of bone composed of rhabdomyosarcoma, osteosarcoma, and a minor chondrosarcoma component, arising in the right proximal humerus of a 15-year-old girl.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus / pathology. Mesenchymoma / pathology. Neoplasms, Multiple Primary / pathology. Osteosarcoma / pathology. Rhabdomyosarcoma / pathology
  • [MeSH-minor] Adolescent. Antimetabolites, Antineoplastic / therapeutic use. Chondrosarcoma / diagnosis. Chondrosarcoma / drug therapy. Chondrosarcoma / pathology. Chondrosarcoma / radiography. Chondrosarcoma / surgery. Combined Modality Therapy. Desmin / analysis. Diagnosis, Differential. Fatal Outcome. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / drug therapy. Fibrosarcoma / pathology. Fibrosarcoma / radiography. Fibrosarcoma / surgery. Humans. Methotrexate / therapeutic use. Neoplasm Proteins / analysis. Osteolysis / etiology. Postoperative Complications / etiology. Pulmonary Embolism / etiology. Sarcoma, Ewing / diagnosis


9. Tannehill-Gregg SH, Sanderson TP, Minnema D, Voelker R, Ulland B, Cohen SM, Arnold LL, Schilling BE, Waites CR, Dominick MA: Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar. Toxicol Sci; 2007 Jul;98(1):258-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign gallbladder adenomas occurred at low incidences in male mice at 20 and 40 mg/kg (area under the curve [AUC] exposures > or = 62 times human exposure at 5 mg/day) and were considered drug related due to an increased incidence of gallbladder mucosal hyperplasia at these doses.
  • Subsequent investigative studies established that the urinary bladder carcinogenic effect was mediated by urolithiasis rather than a direct pharmacologic effect on urothelium.
  • Incidences of subcutaneous liposarcoma in male rats and subcutaneous lipoma in female rats were increased at 50 mg/kg (AUC exposures > or = 48 times human exposure at 5 mg/day) and attributed, in part, to persistent pharmacologic stimulation of preadipocytes.
  • Toxicologically relevant nonneoplastic changes in target tissues included thinning of cortical bone in mice and hyperplastic and metaplastic adipocyte changes in mice and rats.
  • [MeSH-major] Carcinogens. Glycine / analogs & derivatives. Hypoglycemic Agents / toxicity. Oxazoles / toxicity. PPAR alpha / agonists. PPAR gamma / agonists
  • [MeSH-minor] Animals. Carcinogenicity Tests. Dose-Response Relationship, Drug. Female. Male. Mice. Mice, Inbred ICR. Neoplasms / chemically induced. Neoplasms / epidemiology. Neoplasms / pathology. Rats. Rats, Sprague-Dawley. Survival Analysis. Urinalysis

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLYCINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17426106.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Hypoglycemic Agents; 0 / Oxazoles; 0 / PPAR alpha; 0 / PPAR gamma; TE7660XO1C / Glycine; W1MKM70WQI / muraglitazar
  •  go-up   go-down


10. Kasper B, Dietrich S, Mechtersheimer G, Ho AD, Egerer G: Large institutional experience with dose-intensive chemotherapy and stem cell support in the management of sarcoma patients. Oncology; 2007;73(1-2):58-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirty-eight patients with bone (n = 17) and soft tissue sarcomas (n = 21) were included.
  • Apart from haematological complications, no WHO grade III-IV complications were observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy. Sarcoma / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Chondrosarcoma / drug therapy. Chondrosarcoma / surgery. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / surgery. Liposarcoma / drug therapy. Liposarcoma / surgery. Male. Middle Aged. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / surgery. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] : (c) 2008 S. Karger AG, Basel
  • (PMID = 18334832.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Multhaupt HA, Alvarez JC, Rafferty PA, Warhol MJ, Lackman RD: Fluoroquinolone's effect on growth of human chondrocytes and chondrosarcomas. In vitro and in vivo correlation. J Bone Joint Surg Am; 2001;83-A Suppl 2(Pt 1):56-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal human cartilage, enchondroma, and chondrosarcoma explants were cultured either alone or with the addition of ciprofloxacin at 1, 10, or 20 mg/L of medium.
  • Cultures of normal chondrocytes expressed type-II collagen.
  • The treated chondrocytes showed a decrease in cell proliferation, but there was no induction of apoptosis or effect on the expression of extracellular matrix proteins.
  • Ultrastructural analysis demonstrated clumped glycogen, dilation of endoplasmic reticulum, numerous abnormal lysosomes containing degeneration products, and a decreased proteoglycan deposit surrounding the tumor cells.
  • In contrast, the in vitro growth of other noncartilaginous malignant tumors like osteosarcoma and liposarcoma was unaffected by ciprofloxacin.
  • [MeSH-major] Anti-Infective Agents / toxicity. Chondrocytes / drug effects. Chondroma / pathology. Chondrosarcoma / pathology. Ciprofloxacin / toxicity
  • [MeSH-minor] Collagen Type II / biosynthesis. Culture Media. Culture Techniques. Humans. Microscopy, Electron. Tumor Cells, Cultured / drug effects

  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11685846.001).
  • [ISSN] 0021-9355
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Collagen Type II; 0 / Culture Media; 5E8K9I0O4U / Ciprofloxacin
  •  go-up   go-down


12. Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, Dunst J, Harms D, Reiter A, Henze G, Niemeyer C, Göbel U, Kremens B, Fölsch UR, Aulitzky WE, Voûte PA, Zoubek A, Jürgens H: Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol; 2001 Nov;12(11):1619-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Ewing tumor treatment involves high cumulative doses of alkylating agents and topoisomerase inhibitors, drugs capable of inducing second cancers.
  • RESULTS: After a median observation time of 56 months (32 months for survivors), 6 of 690 patients had developed second cancers: MDS/AML, two, ALL/NHL, two, squamous cell carcinoma, one, liposarcoma, one.
  • SIR were increased 20-30 fold in comparison to the general population.
  • The cumulative second cancer risk five years after diagnosis of the Ewing tumor was 0.0093 for the total group, zero for patients without etoposide, and 0.0118 with etoposide.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11822764.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement